Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Tetanus - Overview Tetanus - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Tetanus - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Tetanus - Companies Involved in Therapeutics Development Beijing Minhai Biotechnology Co Ltd Bharat Biotech International Ltd Biological E Ltd Cadila Healthcare Ltd GC Pharma GlaxoSmithKline Plc Indian Immunologicals Ltd Kaketsuken LG Chem Ltd Panacea Biotec Ltd Sanofi Sanofi Pasteur SA Serum Institute of India Ltd Shantha Biotechnics Pvt Ltd Wockhardt Ltd Tetanus - Drug Profiles (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) (tetravalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + Haemophilus influenzae [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + pertussis (whole cell) + tetanus) (trivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress BK-1310 - Drug Profile Product Description Mechanism Of Action R&D Progress DTcP vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress GC-3111A - Drug Profile Product Description Mechanism Of Action R&D Progress KD-370 - Drug Profile Product Description Mechanism Of Action R&D Progress LBVD - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody for Tetanus - Drug Profile Product Description Mechanism Of Action R&D Progress tetanus vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress tetanus vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress tetanus vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Tetanus - Dormant Projects Tetanus - Discontinued Products Tetanus - Product Development Milestones Featured News & Press Releases Nov 24, 2016: Sanofi Pasteur launches India's first 6-in-1 pediatric vaccine - Hexaxim Nov 24, 2016: Sanofi Pasteur launches India's first 6-in-1 pediatric vaccine- Hexaxim Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5 Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA Nov 10, 2014: Shantha’s Pentavalent Pediatric Vaccine launched in India Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine May 05, 2014: Shantha’s Pentavalent Pediatric Vaccine prequalified by World Health Organization Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Pediatric Vaccine In European Markets Jun 22, 2012: Sanofi Pasteur’s Hexaxim Receives Positive Opinion From European Medicines Agency May 11, 2011: Sanofi Pasteur Launches Pentaxim In China Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Tetanus, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Number of Products under Development by Universities/Institutes, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Products under Development by Universities/Institutes, H1 2018 Number of Products by Stage and Target, H1 2018 Number of Products by Stage and Mechanism of Action, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Tetanus - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018 Tetanus - Pipeline by Bharat Biotech International Ltd, H1 2018 Tetanus - Pipeline by Biological E Ltd, H1 2018 Tetanus - Pipeline by Cadila Healthcare Ltd, H1 2018 Tetanus - Pipeline by GC Pharma, H1 2018 Tetanus - Pipeline by GlaxoSmithKline Plc, H1 2018 Tetanus - Pipeline by Indian Immunologicals Ltd, H1 2018 Tetanus - Pipeline by Kaketsuken, H1 2018 Tetanus - Pipeline by LG Chem Ltd, H1 2018 Tetanus - Pipeline by Panacea Biotec Ltd, H1 2018 Tetanus - Pipeline by Sanofi, H1 2018 Tetanus - Pipeline by Sanofi Pasteur SA, H1 2018 Tetanus - Pipeline by Serum Institute of India Ltd, H1 2018 Tetanus - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2018 Tetanus - Pipeline by Wockhardt Ltd, H1 2018 Tetanus - Dormant Projects, H1 2018 Tetanus - Dormant Projects, H1 2018 (Contd..1), H1 2018 Tetanus - Discontinued Products, H1 2018List of Figures Number of Products under Development for Tetanus, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products under Development by Universities/Institutes, H1 2018 Number of Products by Targets, H1 2018 Number of Products by Stage and Targets, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018